{"id":10600,"date":"2022-06-13T10:05:29","date_gmt":"2022-06-13T08:05:29","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=10600"},"modified":"2022-06-13T11:05:36","modified_gmt":"2022-06-13T09:05:36","slug":"imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/","title":{"rendered":"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline"},"content":{"rendered":"

ImCheck Therapeutics<\/a> announced today the close of a EUR\u00a096 million (USD\u00a0103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million – USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million – USD 17.2 Million) solidifies ImCheck\u2019s financial position and leadership in the gamma-delta T cell space. Invus and the Leukemia and Lymphoma Society also joined the round as new investors. Existing investors including the Growth Opportunity Fund of founding investor Kurma Partners, Eurazeo, Gimv, Pfizer Ventures, Bpifrance, Wellington Partners, Pureos Bioventures, Agent Capital and Alexandria Venture Investments participated.<\/p>\n

The proceeds will be used to support the Phase IIa expansion and completion of the randomized, double-blind, placebo-controlled part of the ongoing EVICTION clinical trial evaluating ImCheck\u2019s lead candidate ICT01 as a both monotherapy and in combination with a PD-1 inhibitor for a broad range of cancers including solid tumors and hematologic malignancies. The Company also will apply the capital to investigate ICT01 in combination with other therapeutic agents, including IL-2, in the forthcoming EVICTION-2 clinical trial. The funding will accelerate the further advance toward the clinic of additional antibody candidates in immuno-oncology, auto-immune and infectious diseases. In addition, it will allow the Company to achieve pivotal study readiness for ICT01 and expand its footprint through extended clinical operations and regulatory affairs in Europe and the US.<\/p>\n

\u201cSince its inception, ImCheck has gained the support of a syndicate of outstanding international funds. In a highly challenging funding market, we have secured a significant fundraising through the addition of highly strategic and valuable investors from the U.S. and Europe, putting us in a position to further deliver on the immense promise of our pipeline,\u201d<\/em> stated<\/strong> Pierre d\u2019Epenoux<\/strong><\/a>, Chief Executive Officer of ImCheck Therapeutics. <\/strong>\u201cWe view our singular proprietary position with butyrophilins, which offer powerful immunomodulation of both the innate and adaptive immune systems, as the key to therapeutic intervention for many disease indications and we value the support we are now gaining from the Leukemia and Lymphoma Society as a first investment from a patient-focused organization.\u201d<\/em><\/p>\n

In conjunction with the financing round, Florent Gros (Earlybird) and Rapha\u00ebl Wisniewski (Andera Partners) will join the Company\u2019s Board of Directors.<\/p>\n

Florent Gros, Partner at Earlybird, commented,<\/strong> \u201cImCheck\u2019s approach to immuno-oncology is highly differentiated through the clinical demonstration of gamma-delta T cell activation, an area of immunology that has huge potential and interest from the biopharmaceutical community. At Earlybird, we support companies that dare to think differently and ImCheck\u2019s innovative concept for immunomodulation could be a game-changer for a range of indications.\u201d<\/em><\/p>\n

Rapha\u00ebl Wisniewski, Partner at Andera Partners, said, <\/strong>\u201cImmune checkpoint inhibitors have heralded a new era in cancer treatments and ImCheck Therapeutics is pioneering the next generation of these immunotherapeutics. In watching their progress to date, we have seen the leadership team execute on a compelling vision for a butyrophilin-based therapeutic approach from the early development stage into a highly valuable clinical development program. We at Andera Partners are confident the company will move its groundbreaking technology forward to meet patients\u2019 needs in a range of cancer indications with wider potential for auto-immune and infectious diseases.\u201d<\/em><\/p>\n

ImCheck Therapeutics\u2019 immunotherapeutic technology is capable of overcoming the adaptive antitumor immune response through a novel superfamily of immune checkpoint targets, butyrophilins (BTNs). BTNs can be modulated to harness a wide range of immune cells including gamma-delta T cells, CD3, CD8, NK cells and macrophages, bridging the innate and adaptive immune responses. The company\u2019s broad pipeline is built upon immunomodulation via BTN-targeting antibodies aimed either at activating the immune system in disease indications such as cancer or infectious diseases, or down-regulating immunity in auto-immune disorders.<\/p>\n

Hans Henrik Christensen, Chief Financial Officer of ImCheck Therapeutics, added<\/strong>, \u201cImCheck has now raised a total of EUR\u00a0154\u00a0million and is in an excellent position to build on our initial promising results in the clinic with our lead candidate, ICT01, and continue to lead the field of antibody therapies activating gamma-delta T cells.\u201d<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

ImCheck Therapeutics announced today the close of a EUR\u00a096 million (USD\u00a0103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million – USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million – USD 17.2 Million) solidifies ImCheck\u2019s financial position and…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-10600","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"\nImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"ImCheck Therapeutics announced today the close of a EUR\u00a096 million (USD\u00a0103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million – USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million – USD 17.2 Million) solidifies ImCheck\u2019s financial position and...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T08:05:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-13T09:05:36+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline\",\"datePublished\":\"2022-06-13T08:05:29+00:00\",\"dateModified\":\"2022-06-13T09:05:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/\"},\"wordCount\":696,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/\",\"name\":\"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2022-06-13T08:05:29+00:00\",\"dateModified\":\"2022-06-13T09:05:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/","og_locale":"en_US","og_type":"article","og_title":"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline - ANDERA PARTNERS","og_description":"ImCheck Therapeutics announced today the close of a EUR\u00a096 million (USD\u00a0103 million) financing, co-led by Earlybird and Andera Partners. The Series C round (EUR 80 Million – USD 86 Million) and the last outstanding tranche of Series B converted in Series C shares (EUR 16 Million – USD 17.2 Million) solidifies ImCheck\u2019s financial position and...","og_url":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2022-06-13T08:05:29+00:00","article_modified_time":"2022-06-13T09:05:36+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline","datePublished":"2022-06-13T08:05:29+00:00","dateModified":"2022-06-13T09:05:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/"},"wordCount":696,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/","url":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/","name":"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2022-06-13T08:05:29+00:00","dateModified":"2022-06-13T09:05:36+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/imcheck-annonce-la-cloture-dun-tour-de-financement-de-96-millions-deuros-103-millions-de-dollars-us-pour-avancer-la-validation-clinique-de-son-anticorps-activateur-des-lymphocytes-t-gamma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Validation of First-in-human Gamma-delta 2 T Cell Activating Antibody and Accelerate Development of Disruptive Immuno-oncology Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/10600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=10600"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/10600\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=10600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=10600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}